About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Bosutinib For Autosomal Dominant Polycystic Kidney Disease

NCT01233869·67 sites·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Pfizer

Age

18–50

Sex

ALL

Healthy volunteers

Not accepted

You may be eligible if

Males and females, 18 to 50 years old at the time of consent.
Documented diagnosis of ADPKD (PKD-1 or PKD-2 genotypes allowed).
Total kidney volume ≥ 750 cc, as measured by centrally evaluated MRI.

You may not be if

eGFR \< 60 mL/min/1.73m2.
Uncontrolled hypertension (defined as systolic blood pressure ≥140 or diastolic blood pressure ≥90 mm Hg).
Any previous exposure to the bosutinib test article or receipt of other polycystic kidney disease (PKD) therapies.

The record

StatusCompleted

PhasePhase 2

Taking part172

StartedDec 2010

UpdatedMar 11, 2016

Conditions

Polycystic Kidney, Autosomal Dominant

Where67

Southwest Kidney Institute, PLC
Phoenix, Arizona, United States
Southwest Clinical Research Institute, LLC
Tempe, Arizona, United States
Southwest Kidney Institute, PLC
Tempe, Arizona, United States

Clareo Health | Bosutinib For Autosomal Dominant Polycystic Kidney Disease